CA2903433A1 - Stable glucokinase activator compositions - Google Patents

Stable glucokinase activator compositions Download PDF

Info

Publication number
CA2903433A1
CA2903433A1 CA2903433A CA2903433A CA2903433A1 CA 2903433 A1 CA2903433 A1 CA 2903433A1 CA 2903433 A CA2903433 A CA 2903433A CA 2903433 A CA2903433 A CA 2903433A CA 2903433 A1 CA2903433 A1 CA 2903433A1
Authority
CA
Canada
Prior art keywords
cyclohexyl
propoxy
acetic acid
trans
ureido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2903433A
Other languages
English (en)
French (fr)
Inventor
Yun Mo
Mahendra G. Dedhiya
Anil Chhettry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
vTv Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by vTv Therapeutics LLC filed Critical vTv Therapeutics LLC
Publication of CA2903433A1 publication Critical patent/CA2903433A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2903433A 2013-03-04 2014-02-28 Stable glucokinase activator compositions Abandoned CA2903433A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361772022P 2013-03-04 2013-03-04
US61/772,022 2013-03-04
PCT/US2014/019349 WO2014137797A2 (en) 2013-03-04 2014-02-28 Stable glucokinase activator compositions

Publications (1)

Publication Number Publication Date
CA2903433A1 true CA2903433A1 (en) 2014-09-12

Family

ID=50424705

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2903433A Abandoned CA2903433A1 (en) 2013-03-04 2014-02-28 Stable glucokinase activator compositions

Country Status (11)

Country Link
US (1) US20160015638A1 (enExample)
EP (1) EP2964198A2 (enExample)
JP (1) JP6441828B2 (enExample)
KR (1) KR20150123838A (enExample)
CN (1) CN105050585A (enExample)
AU (1) AU2014226290B2 (enExample)
CA (1) CA2903433A1 (enExample)
HK (1) HK1213780A1 (enExample)
IL (1) IL240735A0 (enExample)
MX (1) MX2015011109A (enExample)
WO (1) WO2014137797A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2576524T (pt) 2010-05-26 2017-11-17 Vtv Therapeutics Llc Resumo
IN2014DN09554A (enExample) 2012-05-17 2015-07-17 Transtech Pharma Llc
DK3556354T3 (da) * 2016-12-15 2025-08-04 Hua Medicine Shanghai Ltd Oral fremstilling af en glucokinaseaktivator og fremgangsmåde til fremstilling deraf
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US11857536B2 (en) 2020-06-04 2024-01-02 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
CA3185831A1 (en) * 2020-06-04 2021-12-09 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
CA3181665A1 (en) * 2020-06-08 2021-12-16 Jing TENG Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof
US12479808B2 (en) * 2020-06-08 2025-11-25 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
KR20240084229A (ko) * 2022-12-06 2024-06-13 유노비아 주식회사 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
PT1429731E (pt) * 2001-09-19 2007-04-30 Elan Pharma Int Ltd Formulações de insulina nanoparticulada
ATE419835T1 (de) * 2002-05-06 2009-01-15 Elan Pharma Int Ltd Nystatin-nanopartikelzusammensetzungen
EP1511467A1 (en) * 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
AU2003241478A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd. Nanoparticulate sterol formulations and sterol combinations
BRPI0506662B8 (pt) * 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
JP2008524239A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド ナノ粒子のタクロリムス製剤
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
CN101132770A (zh) * 2005-01-06 2008-02-27 伊兰制药国际有限公司 纳米微粒坎地沙坦制剂
KR20080003322A (ko) * 2005-02-24 2008-01-07 엘란 파마 인터내셔널 리미티드 도세탁셀 및 이의 유사체의 나노입자 배합물
WO2006102117A1 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
US20060210638A1 (en) * 2005-03-17 2006-09-21 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
CN101212954A (zh) * 2005-05-10 2008-07-02 伊兰制药国际有限公司 纳米粒氯吡格雷制剂
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
EA015102B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Препараты наночастиц мезилата иматиниба
WO2007053197A2 (en) * 2005-06-03 2007-05-10 Elan Pharma International, Limited Nanoparticulate acetaminophen formulations
ATE446742T1 (de) * 2005-06-09 2009-11-15 Elan Pharma Int Ltd Nanopartikuläre ebastinformulierungen
WO2007008537A2 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
CN101495096A (zh) * 2006-05-30 2009-07-29 伊兰制药国际有限公司 纳米微粒泊沙康唑制剂
WO2008066899A2 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
JP5419706B2 (ja) * 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
US20090028680A1 (en) * 2007-07-27 2009-01-29 Kling Troy L Intermediate apparatus for towing utility vehicles
JP5513492B2 (ja) * 2008-05-16 2014-06-04 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
US8054567B2 (en) * 2008-07-23 2011-11-08 Hitachi High-Technologies Corporation Method for measuring write/read width of a composite magnetic head and a measuring device using the method
EP2442789A1 (en) * 2009-06-18 2012-04-25 Abbott Laboratories Stable nanoparticulate drug suspension
CN102497858B (zh) * 2009-06-19 2015-03-04 纳米模型匈牙利有限公司 纳米颗粒替米沙坦组合物及其制备方法
CN101829061A (zh) * 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
PT2576524T (pt) * 2010-05-26 2017-11-17 Vtv Therapeutics Llc Resumo

Also Published As

Publication number Publication date
JP6441828B2 (ja) 2018-12-19
WO2014137797A3 (en) 2014-10-30
MX2015011109A (es) 2015-11-16
US20160015638A1 (en) 2016-01-21
EP2964198A2 (en) 2016-01-13
AU2014226290A1 (en) 2015-10-08
HK1213780A1 (zh) 2016-07-15
IL240735A0 (en) 2015-10-29
CN105050585A (zh) 2015-11-11
KR20150123838A (ko) 2015-11-04
AU2014226290B2 (en) 2018-11-15
WO2014137797A2 (en) 2014-09-12
JP2016513625A (ja) 2016-05-16

Similar Documents

Publication Publication Date Title
AU2014226290B2 (en) Stable glucokinase activator compositions
US20250288681A1 (en) Solid compositions comprising a glucokinase activator and methods of making and using the same
EP3556354B1 (en) Oral preparation of glucokinase activator and preparation method therefor
US20230321246A1 (en) High-strength oral taxane compositions and methods
US20240207239A1 (en) Composition and preparation method therefor
CN100560067C (zh) 盐酸决奈达隆口服药物组合物及其制备方法
WO2008077591A2 (en) Pharmaceutical formulation comprising neurokinin antagonist
EP3620156A1 (en) Composition having improved water solubility and bioavailability
JP2021059551A (ja) フェニルアミノピリミジン誘導体を含む医薬組成物
EP3305282A2 (en) Composition of pranlukast-containing solid preparation with improved bioavailability and method for preparing same
CN121818963A (zh) 维拉佐酮包合物及其组合物和制备方法
KR20220077094A (ko) 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물
CN114948960A (zh) 一种维拉佐酮的组合物及其制备方法
US12171761B2 (en) Vilazodone inclusion complexes, compositions and preparation thereof
CN116687961A (zh) 一种含有兰索拉唑及碳酸氢钠的干混悬剂及其制备方法
JP7582961B2 (ja) 6,7-不飽和-7-カルバモイルモルヒナン誘導体含有固形製剤
WO2023034844A1 (en) Delayed release niclosamide formulation
WO2023227997A1 (en) Pharmaceutical composition containing combination of azilsartan and chlorthalidone and process of preparation thereof
HK40027115A (en) Solid dispersion

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200228